Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy

Am J Physiol Renal Physiol. 2016 Mar 15;310(6):F547-59. doi: 10.1152/ajprenal.00574.2014. Epub 2015 Dec 30.

Abstract

Oxidative stress is implicated in the pathogenesis of diabetic kidney injury. SS-31 is a mitochondria-targeted tetrapeptide that can scavenge reactive oxygen species (ROS). Here, we investigated the effect and molecular mechanism of mitochondria-targeted antioxidant peptide SS-31 on injuries in diabetic kidneys and mouse mesangial cells (MMCs) exposed to high-glucose (HG) ambience. CD-1 mice underwent uninephrectomy and streptozotocin treatment prior to receiving daily intraperitoneal injection of SS-31 for 8 wk. The diabetic mice treated with SS-31 had alleviated proteinuria, urinary 8-hydroxy-2-deoxyguanosine level, glomerular hypertrophy, and accumulation of renal fibronectin and collagen IV. SS-31 attenuated renal cell apoptosis and expression of Bax and reversed the expression of Bcl-2 in diabetic mice kidneys. Furthermore, SS-31 inhibited expression of transforming-growth factor (TGF)-β1, Nox4, and thioredoxin-interacting protein (TXNIP), as well as activation of p38 MAPK and CREB and NADPH oxidase activity in diabetic kidneys. In vitro experiments using MMCs revealed that SS-31 inhibited HG-mediated ROS generation, apoptosis, expression of cleaved caspase-3, Bax/Bcl-2 ratio, and cytochrome c (cyt c) release from mitochondria. SS-31 normalized mitochondrial potential (ΔΨm) and ATP alterations, and inhibited the expression of TGF-β1, Nox4, and TXNIP, as well as activation of p38 MAPK and CREB and NADPH oxidase activity in MMCs under HG conditions. SS-31 treatment also could reverse the reduction of thioredoxin (TRX) biologic activity and upregulate expression of thioredoxin 2 (TRX2) in MMCs under HG conditions. In conclusion, this study demonstrates a protective effect of SS-31 against HG-induced renal injury via an antioxidant mechanism in diabetic nephropathy.

Keywords: SS-31 peptide; apoptosis; diabetic nephropathy; mitochondria; oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Carrier Proteins / metabolism
  • Cells, Cultured
  • Collagen Type IV / metabolism
  • Cyclic AMP Response Element-Binding Protein / metabolism
  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / metabolism
  • Drug Evaluation, Preclinical
  • Fibronectins / metabolism
  • Glucose
  • Male
  • Mice
  • Mitochondria / drug effects*
  • Mitochondria / metabolism
  • NADPH Oxidase 4
  • NADPH Oxidases / metabolism
  • Oligopeptides / pharmacology
  • Oligopeptides / therapeutic use*
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Reactive Oxygen Species / metabolism
  • Thioredoxins / metabolism
  • Transforming Growth Factor beta1 / metabolism
  • bcl-2-Associated X Protein / metabolism
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Carrier Proteins
  • Collagen Type IV
  • Creb1 protein, mouse
  • Cyclic AMP Response Element-Binding Protein
  • Fibronectins
  • Oligopeptides
  • Proto-Oncogene Proteins c-bcl-2
  • Reactive Oxygen Species
  • Tgfb1 protein, mouse
  • Transforming Growth Factor beta1
  • Txnip protein, mouse
  • arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide
  • bcl-2-Associated X Protein
  • Thioredoxins
  • NADPH Oxidase 4
  • NADPH Oxidases
  • Nox4 protein, mouse
  • p38 Mitogen-Activated Protein Kinases
  • Glucose